Can a fullness score help curb overeating?
NCT ID NCT07530939
First seen Jun 27, 2026 · Last updated Oct 01, 2026 · Updated 2 times
Summary
This study looks at a new idea called 'satiety per calorie' (SPC) — how full a food makes you feel for each calorie it contains. Researchers will give 40 healthy men different foods and measure how much they eat. The goal is to see if foods with higher SPC help people eat less without feeling hungry, which could lead to better diets and fight obesity.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could help design foods that make people feel full with fewer calories, potentially aiding weight management.
- What could go wrong
- This is an early observational study with only 40 healthy men, so results may not apply to everyone. It measures food intake in a lab, not real-world eating habits.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 40 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2026
- Expected to finish
-
Jul 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 44 years
- Sex
-
Male participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Body mass index (BMI) between 18.5 and 28 kg/m2 * Male * 18-44 years old * Healthy Exclusion Criteria: * No diabetes, infectious diseases, gastrointestinal disorders, hypoglycemia, cardiovascular or cerebrovascular diseases, mental illnesses, etc. * Not being allergic to common foods. * No special dietary habits, eating disorders, irregular eating or lifestyle patterns, or smoking and drinking habits.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Shenzhen Institutes of advanced technology
RECRUITINGShenzhen, Guangdong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Three-Arm study to evaluate the effects of 3-Week supplementation with single (THRIVE4U(TM) TG lipase) and combination lipase (THRIVE4U(TM) spectrum lipases) products on increasing fatty acid absorption in generally healthy adults with potential exocrine pancreatic dysfunction
- Mapping of vestibular center activation using fMRI in patients with vestibular schwannoma
- WIM exosuit wearable soft robot for enhancing walking activity
- A single-sequence, open-label, three-period, crossover study to evaluate the effect of rabeprazole, a proton pump inhibitor, on pharmacokinetics of DZD8586 (Birelentinib) in healthy participants
- Comparative effect of training methods to reduce forefoot loading in carbon fiber custom dynamic orthoses
- Pulmonary immune cell-microbiome interactions in the healthy lung: the ILLUMINA-2 study